drugset / Trial / NCT04604678

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

NCT04604678

Phase 2 Withdrawn AgelessRx
RandomizedParallel-groupOpen-labelTreatment

Summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

Timeline

Start
2021-02
Primary completion
2021-08
Completion
2021-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1500 mg
Subject Naltrexone Small molecule 4.5 mg

Indications